Higher dexamethasone clearance and anti–asparaginase antibodies were associated with cumulative incidence of CNS relapse
| Factors* . | Hazard ratio . | 95% CI . | P† . |
|---|---|---|---|
| Dexamethasone CL/F (L/h per m2) per 50-unit change‡ | 1.93 | 1.1-3.27 | .014 |
| Anti–ASP antibody positive vs negative | 6.58 | 1.36-31.9 | .019 |
| Older than 10 years vs 1-10 years | 0.37 | 0.09-1.5 | .16 |
| Initial leukocyte count ≥ 100 cells/mm3 vs < 100 cells/mm3 | 1.56 | 0.28-8.67 | .61 |
| Black vs white§ | 1.81 | 0.51-6.35 | .36 |
| Other vs white§ | 1.56 | 0.14-17.6 | .72 |
| T-lineage vs B-lineage‖ | 3.55 | 0.65-19.3 | .14 |
| t(1;19)[TCF3-PBX1] vs absent¶ | 6.40 | 0.93-43.9 | .06 |
| Others vs CNS1# | 4.62 | 1.55-13.8 | .0061 |
| SR/HR vs LR | 9.33 | 0.74-117 | .084 |
| Factors* . | Hazard ratio . | 95% CI . | P† . |
|---|---|---|---|
| Dexamethasone CL/F (L/h per m2) per 50-unit change‡ | 1.93 | 1.1-3.27 | .014 |
| Anti–ASP antibody positive vs negative | 6.58 | 1.36-31.9 | .019 |
| Older than 10 years vs 1-10 years | 0.37 | 0.09-1.5 | .16 |
| Initial leukocyte count ≥ 100 cells/mm3 vs < 100 cells/mm3 | 1.56 | 0.28-8.67 | .61 |
| Black vs white§ | 1.81 | 0.51-6.35 | .36 |
| Other vs white§ | 1.56 | 0.14-17.6 | .72 |
| T-lineage vs B-lineage‖ | 3.55 | 0.65-19.3 | .14 |
| t(1;19)[TCF3-PBX1] vs absent¶ | 6.40 | 0.93-43.9 | .06 |
| Others vs CNS1# | 4.62 | 1.55-13.8 | .0061 |
| SR/HR vs LR | 9.33 | 0.74-117 | .084 |
ASP indicates asparaginase.
Prognostic features included in this model are known to be associated with treatment outcome in St Jude Total XV cohort by univariate analysis.9
P value from multivariate analysis using Fine and Gray regression model.18
Dexamethasone clearance is continuous variable, and the hazard ratio is calculated for every 50-unit change in clearance.
Genetically determined race as described.10
Acute lymphoblastic leukemia immunophenotype.
t(1;19)[TCF3-PBX1] included in analysis because it was associated with CNS relapse.9
CNS1 (no detectable blast cells in a sample of cerebrospinal fluid) vs other CNS status: CNS2 (< 5 leukocytes per cubic millimeter with blast cells in a sample with < 10 erythrocytes per cubic millimeter) and CNS3 (≥ 5 leukocytes per cubic millimeter with blast cells in a sample with < 10 erythrocytes per cubic millimeter or the presence of a cranial nerve palsy), and traumatic lumbar puncture with blast cells (≥ 10 erythrocytes per cubic millimeter with blast cells.